AMAG Pharmaceuticals, Inc. provided earnings guidance for the fourth quarter and full year of 2015 and 2016. For the quarter, the company expects total non-GAAP product revenue of between $116 million and $124 million, which includes net product sales for Makena® (hydroxyprogesterone caproate injection) of between $66 million and $70 million and for Feraheme® (ferumoxytol) injection and MuGard® of between $22 million and $24 million. Non-GAAP CBR revenue is expected to be between $28 million and $30 million, which includes a purchase accounting adjustment to deferred revenue. On a GAAP basis, total product revenue is expected to be between $104 million and $112 million and CBR revenue is expected to be between $16 million and $18 million. The weighted average basic and non-GAAP diluted shares outstanding for the fourth quarter of 2015 totaled 34.7 million and 41.6 million, respectively.

For the full year 2015, the company expects total non-GAAP revenue of between $431 million and $441 million. Net product sales in 2015 are expected to be between $250 million and $254 million for Makena and between $89 million and $91 million for Feraheme and MuGard combined. CBR revenue is expected to be between $42 million and $44 million on a non-GAAP basis, which includes a purchase accounting adjustment to deferred revenue. On a GAAP basis, total revenue is expected to be between $412 million and $422 million and CBR revenue is expected to be between $23 million and $25 million. The company ended 2015 with $467 million in cash and investments and total debt of $1.05 billion.

For the full year 2016, the company expects non-GAAP CBR revenue between $115 million - $125 million, total revenue between $520 million - $570 million, GAAP net income between $11 million - $41 million, depreciation and amortization of $90 million, interest expense, net of $72 million, EBITDA between $210 million - $240 million, non-GAAP adjusted EBITDA between $255 million - $285 million and non-GAAP cash earnings between $195 million - $225 million.